OSM/OSMRβ轴塑造MASLD相关HCC免疫抑制微环境
本研究探讨OSM/OSMRβ轴在MASLD相关肝细胞癌免疫抑制肿瘤微环境中的作用。通过患者样本、肝细胞特异性OSMRβ敲除小鼠及体外实验,发现OSM通过自分泌方式促进肿瘤细胞产生CCL15,进而刺激免疫抑制微环境,OSM或为潜在治疗靶点。
要点
- OSM/OSMRβ轴通过自分泌促进HCC细胞产生CCL15。
- 肝细胞OSMRβ敲除减少小鼠MASH-HCC肿瘤体积和重量。
- OSM可能成为MASH-HCC免疫治疗的新靶点。
核心结论
- OSM/OSMRβ轴通过自分泌促进肿瘤细胞产生CCL15,塑造MASH-HCC免疫抑制微环境,OSM是潜在治疗靶点。
研究设计与样本
- 结合MASLD/MASH伴或不伴HCC患者分析、野生型与肝细胞特异性OSMRβ敲除小鼠的MASH相关HCC模型及体外实验。
主要发现
- OSM转录本与多个TIME标志物正相关,在TCGA混合病因HCC患者和小鼠MASH-HCC肿瘤中均观察到此模式。
- hOSMRβ-/-小鼠肿瘤体积和重量显著减少,巨噬细胞浸润和OSM产生未变,但TIME标志物转录本降低。
- hOSMRβ缺失降低肿瘤STAT3磷酸化和COX-2活性,并显著降低人和啮齿类MASH-HCC中升高的循环CCL15。
- 单细胞RNA-seq识别恶性肝细胞为CCL15来源,阻断HepG2或Huh7细胞自分泌OSM信号减少STAT3磷酸化、CCL15产生及共培养巨噬细胞TIME标志物表达。
临床怎么用
- OSM/OSMRβ轴及下游CCL15可能作为MASH-HCC免疫治疗干预靶点,需进一步临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Oncostatin M (OSM) has been shown to contribute to metabolic dysfunction-associated steatohepatitis (MASH) progression to hepatocellular carcinoma (HCC). Here, we investigated its role in shaping an immunosuppressive tumor microenvironment (TIME) in MASH-HCCs. APPROACH AND RESULTS: OSM role was investigated through combined analyses of MASLD/MASH patients with or without HCC, MASH-related HCCs originating in wild-type and hepatocyte-specific OSM receptor-β (hOSMRβ -/- ) deficient mice, and in vitro experiments performed on liver cancer and immune cell lines. Analysis of OSM-expressing HCC patients with mixed etiology (TCGA-database) revealed a positive correlation between OSM transcripts and those of several TIME markers. A similar pattern was also observed in murine MASH-HCC tumors. hOSMRβ -/- mice had significantly reduced tumor volume and weight without altering macrophage infiltration and OSM production. However, TIME markers transcripts were lower in HCCs from hOSMRβ -/- mice. These effects are associated with a lowering in tumor STAT3 phosphorylation and COX-2 activity. Single-cell RNA-seq analysis of human HCCs identified malignant hepatocytes as the source of CCL15, a cytokine associated with immunosuppression in HCCs. Circulating CCL15 was markedly elevated in both human and rodent MASH-HCCs and significantly reduced by hOSMRβ deletion. Blocking autocrine OSM signaling in HepG2 or Huh7 cells overexpressing OSM reduced STAT3 phosphorylation, CCL15 production, and prevented TIME markers expression by co-cultured macrophage-derived THP-1 cells. CONCLUSIONS: Our findings provide compelling evidence for an autocrine role of the OSM/OSMRβ axis in promoting CCL15 production by tumor cells, which, in turn, stimulates an immunosuppressive TIME in MASH-HCCs, suggesting OSM as a potential therapeutic target for HCC treatment.
引用
- Nurcis J, Foglia B, Rosso C, et al. The role of OSM/OSMRβ axis in shaping the tumor microenvironment favoring MASLD-related HCC immune evasion. Hepatology. 2026. PMID: 41779954. doi:10.1097/HEP.0000000000001733
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。